In contrast, acquired resistance arises after an initial response to therapy, when the tumor adapts by upregulating alternative immune checkpoints like TIM-3 or LAG-3 or by recruiting immunosuppressive cells like Tregs, MDSCs, and TAMs [53]. Here, LAG3 is linked to neoplasm.